Latest Investments News

Mako Gold Limited reported a challenging quarter with significant cash outflows and has drawn $500,000 from a $1.5 million loan facility linked to Aurum Resources’ takeover offer. The company’s available funding now covers less than one quarter of its operational needs.

Avecho Biotechnology progresses its Phase III clinical trial for a TPM®-enhanced CBD insomnia capsule, expands patient recruitment, and completes a major manufacturing campaign for its U.S. partner Ashland.

Magnum Mining and Exploration Limited reported a net cash outflow of $87.68k for Q4 2024, ending the quarter with $332.81k in cash and a substantial $11 million in unused financing facilities.

Zenith Minerals reported a 40% increase in its Dulcie Far North gold resource and secured A$2.48 million in new funding, positioning the company for aggressive exploration across its Australian gold and lithium projects.

Beam Dental Bidco Pty Ltd has extended its off-market takeover offer for Pacific Smiles Group Limited, pushing the closing date to 11 February 2025. This move signals continued strategic interest and keeps the acquisition prospects open.

A1 Investments & Resources Ltd reports a modest cash outflow for the June 2024 quarter while actively pursuing acquisitions and planning convertible note funding to support growth.

NSX Limited reports a $1.6 million cash injection from ISXFEU, completes the ClearPay joint venture sale, and reduces operational costs in its 2Q25 activities report, while facing delays in share issuance approval.

BlinkLab has launched its pivotal FDA registrational study for its AI-driven autism diagnostic app, BlinkLab Dx 1, following positive FDA feedback and promising preliminary results.

Impact Minerals Limited reported its December 2024 quarterly cash flow, revealing ongoing exploration expenditures and a significant $2.87 million grant to commercialise its High Purity Alumina process at Lake Hope.

NH3 Clean Energy has made significant strides in its WAH2 Project, finalising critical commercial agreements and progressing technical work ahead of Front End Engineering and Design (FEED) entry scheduled for Q1 2025. The company also completed a capital raise to support these developments.

Bluechiip Limited remains in ASX suspension as it finalises its 2024 audited accounts, while its ongoing Strategic Review and BioLife deal set the stage for a pivotal 2025 focused on revenue growth and cash-flow break-even.

Bluechiip Limited reported a $221,000 net cash outflow for Q2 FY2025, with cash reserves dwindling to $121,000. The company has initiated a strategic review and plans a capital raise to secure its future.